Accelerated Approval Status Disclosure Would Be Mandated By Markey Bill
Executive Summary
Manufacturers would be required to inform patients and physicians when a product has been approved through the accelerated approval process under legislation to be introduced by Rep. Ed Markey (D-Mass.)
You may also be interested in...
Oncology Advisory Cmte. To Review Unfulfilled Accelerated Approval Trials
FDA's Oncologic Drugs Advisory Committee will review products with unfulfilled accelerated approval postmarketing commitments during an upcoming meeting
Oncology Advisory Cmte. To Review Unfulfilled Accelerated Approval Trials
FDA's Oncologic Drugs Advisory Committee will review products with unfulfilled accelerated approval postmarketing commitments during an upcoming meeting
Iressa Relabeling Reflects Competing Risk/Benefit Interests – CDER’s Galson
FDA's decision to limit the use of Iressa (gefitinib) is indicative of the agency's attempt to incorporate competing interests in a risk/benefit analysis, Center for Drug Evaluation & Research Acting Director Steven Galson said June 21